What Impact Will Gene Therapy Deals Have on Patients? Start-Ups? Jay Duker, MD, Can Speak for Both

We dip into the gene therapy pool one more time, talking with Jay Duker, MD about Luxturna’s impact on ophthalmology. We also discuss how the acquisitions of Spark and Nightstar are benefiting earlier-stage gene therapy start-ups, including his own Hemera Biosciences.